Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-2: navitoclax plus ruxolitinib versus best available therapy in relapsed/refractory myelofibrosis
MOH_2020-07-22_009059Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of navitoclax and ruxolitinib in myelofibrosis (MF) (2 arms), sponsored by AbbVie Inc. Started Jun 2020; status: active, not recruiting.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2020-07-22_009059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-22_009059.